


SSAA09E3

Cat. No.:	HY-138102
CAS No.:	52869-18-8
Molecular Formula:	C ₂₁ H ₁₃ NO ₃
Molecular Weight:	327.33
Target:	SARS-CoV
Pathway:	Anti-infection
Storage:	4°C, protect from light * In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)



SOLVENT & SOLUBILITY

In Vitro

DMSO : 33.33 mg/mL (101.82 mM; ultrasonic and warming and heat to 60°C)

Solvent	Mass	Concentration		
		1 mg	5 mg	10 mg
Preparing Stock Solutions	1 mM	3.0550 mL	15.2751 mL	30.5502 mL
	5 mM	0.6110 mL	3.0550 mL	6.1100 mL
	10 mM	0.3055 mL	1.5275 mL	3.0550 mL

Please refer to the solubility information to select the appropriate solvent.

BIOLOGICAL ACTIVITY

Description	SSAA09E3 is a SARS-CoV entry inhibitor that inhibits SARS/HIV pseudotyped virus entry with an EC ₅₀ of 9.7 μM in 293T cells and inhibits SARS-CoV infection of Vero cells with an EC ₅₀ of 0.15 μM ^{[1][2]} .
IC ₅₀ & Target	SARS-CoV ^[1]
In Vitro	SSAA09E3 blocks viral entry by inhibiting fusion of the viral membrane with the host cell membrane ^[1] . SSAA09E3 inhibits later stages of viral entry ^[2] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

- [1]. Ghosh AK, et al. Drug Development and Medicinal Chemistry Efforts toward SARS-Coronavirus and Covid-19 Therapeutics. ChemMedChem. 2020 Jun 4;15(11):907-932.
- [2]. Adedeji AO, et al. Novel inhibitors of severe acute respiratory syndrome coronavirus entry that act by three distinct mechanisms. J Virol. 2013 Jul;87(14):8017-28.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA